Mcl-1 inhibitors and methods of use thereof

US11472816B2 · kind B2 · utility

Assignee

• ASTRAZENECA AB · SE

Inventors

• Alexander Hird · Belmont, US
• Matthew BELMONTE · Waltham, US
• Wenzhan Yang · Waltham, US
• Paul SECRIST · Waltham, US
• Daniel W. ROBBINS · Waltham, US
• Steven Kazmirski · Sherborn, US
• Dedong Wu · Newton, US
• Bo Peng · Waltham, US
• Jeffrey Wallace Johannes · Waltham, US
• Michelle Lamb · Waltham, US
• Qing Ye · Westborough, US
• Xiaolan Zheng · Waltham, US

Key dates

• Filing date: Dec 4, 2020
• Grant date: Oct 18, 2022
• Expiry date: Jan 13, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D515/22
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Disclosed is a compound which is 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid (Formula I) and enantiomers and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions of 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid, and enantiomers and pharmaceutically acceptable salts thereof, and methods of treating cancer with such compounds and compositions.